Table 4 Therapeutic regimens and length of stay based on the outcome
From: Predictors of mortality of hospitalized COVID-19 pneumonia patients in university hospital
Survivors group (n = 147) | Non-survivor group (n = 104) | p-value | |
|---|---|---|---|
Hospital stay (days) | 12.07 ± 4.64 | 19.71 ± 5.46 | < 0.001 |
Admission to ICU | 38 (25.9%) | 88 (84.6%) | < 0.001 |
NIV | 29 (19.7%) | 73 (70.2%) | < 0.001 |
MV | 2 (1.4%) | 57 (54.8%) | < 0.001 |
Vapotherm | 17 (11.6%) | 27 (26%) | < 0.001 |
Enoxaparin sodium use | 127 (86.4%) | 96 (92.3%) | 0.07 |
NOAC | 3 (2%) | 3 (2.9%) | 0.48 |
Warfarin | 4 (2.7%) | 6 (5.8%) | 0.18 |
Oseltamivir | 32 (21.8%) | 10 (9.6%) | 0.01 |
Remdesivir | 28 (19%) | 34 (32.7%) | 0.01 |
Steroid therapy | 124 (84.4%) | 98 (94.2%) | 0.01 |
Steroid dose (mg) | 148.17 ± 98.76 | 300.82 ± 142.87 | < 0.001 |
Steroid duration (days) | 9.01 ± 2.34 | 11.87 ± 3.31 | 0.02 |
Tocilizumab | 17 (11.6%) | 18 (17.3%) | 0.14 |
Hydroquine | 29 (19.7%) | 6 (5.8%) | < 0.001 |
ICU duration (days) | 5.90 ± 2.34 | 9.71 ± 3.36 | < 0.001 |